

XXII

L

I

V

O

R

N

O

NIBIT



MEETING

At the leading edge
of cancer biotherapy

23-25
OCTOBER 2025

Accademia Navale

NIBIT BOARD

Paolo Ascierto, Napoli - IT
Matteo Bellone, Milano - IT
Vincenzo Bronte, Padova - IT
Giulia Casorati, Milano - IT
Mario Paolo Colombo, Milano - IT
Paola Nisticò, Roma - IT
Arsela Prelaj, Milano - IT
Maria Rescigno, Milano - IT
Antonio Sica, Milano - IT
Claudio Tripodo, Milano - IT

NIBIT JUNIOR FACULTY

Roberta Sommaggio, Padova - IT
Beatrice Belmonte, Palermo - IT
Matteo Benelli, Firenze - IT
Roberto Ferrara, Milano - IT
Sheila Spada, Roma - IT
Marcella Tazzari, Meldola - FC

FACULTY

Paolo Ascierto	Istituto Nazionale Tumori “Fondazione G. Pascale” (Napoli, Italy)
Beatrice Belmonte	Università degli Studi di Palermo (Palermo, Italy)
Matteo Benelli	Università degli Studi di Firenze (Firenze, Italy)
Chiara Bonini	Università Vita-Salute San Raffaele (Milano, Italy)
Vincenzo Bronte	Università degli Studi di Verona (Verona, Italy)
Tina Cascone	MD Anderson Cancer Center (Houston, USA)
Mario Paolo Colombo	IRCCS Istituto Nazionale dei Tumori (Milano, Italy)
Marco Colonna	Washington University School of Medicine (St. Louis, USA)
Flavio Curnis	IRCCS Ospedale San Raffaele (Milano, Italy)
Lorenzo D’ambrosio	Università degli Studi di Torino (Torino, Italy)
Ruggero De Maria	Università Cattolica (Roma, Italy)
Roberto Ferrara	Università Vita-Salute San Raffaele (Milano, Italy)
Pier Francesco Ferrucci	Gruppo Multimedica (Milano, Italy)
Jennifer Guerriero	Harvard Medical School (Boston, USA)
Isaias Hernandez	Centre de Recherche des Cordeliers (Paris, France)
Guido Kroemer	Université Paris-Descartes (Paris, France)
Sara Lonardi	Istituto Oncologico Veneto (Padova, Italy)
Gioacchino Natoli	Istituto Europeo di Oncologia (Milano, Italy)
Dario Neri	Philogen & ETH (Zürich, Switzerland)
Paola Nisticò	Istituto Nazionale Tumori Regina Elena (Roma, Italy)
Renato Ostuni	Università Vita-Salute San Raffaele (Milano, Italy)
Silvia Piconese	Sapienza Università di Roma (Roma, Italy)
Arsela Prelaj	Istituto Nazionale dei Tumori (Milano, Italy)
Concetta Quintarelli	Ospedale Pediatrico Bambino Gesù (Roma, Italy)
Maria Rescigno	Humanitas University (Milano, Italy)
Antonio Sica	Università del Piemonte Orientale (Novara, Italy)
Sheila Spada	Istituto Nazionale Tumori Regina Elena (Roma, Italy)
Roberta Sommaggio	Università degli Studi di Padova (Padova, Italy)
Marcella Tazzari	Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (Meldola, Italy)
Claudio Tripodo	Università degli Studi di Milano (Milano, Italy)
Daniel Truhn	Aachen University (Aachen, Germany)
Laurence Zitvogel	Université Paris-Saclay (Paris, France)

12:00 | Arrival and Registration

13:30 | Welcome addresses

13:45 | INAUGURAL KEYNOTE LECTURE

Chair: Vincenzo Bronte

Guido Kroemer (Paris, France)

Turning Danger into Cure:

The Immuno-Oncology Potential of the Danger Theory

SESSION 1
MYELOID CELLS IN CANCER
Chairs: Roberto Ferrara, Antonio Sica

14:25 | **Jennifer Guerriero (Boston, USA)**

*Unraveling the complexities of tumor associated macrophages
for anti-cancer therapy*

14:45 | Selected abstract

14:55 | Selected abstract

15:05 | Selected abstract

15:15 | General discussion

THURSDAY

SESSION 2
UNCOVERING THE MOLECULAR INTERACTIONS WITHIN
THE TUMOR MICROENVIRONMENT
Chairs: Beatrice Belmonte, Paola Nisticò

15:40 | **Renato Ostuni (Milano, Italy)**
Molecular and spatial organization of the immune tumor microenvironment

16:00 | Selected abstract

16:10 | Selected abstract

16:20 | Selected abstract

16:30 | **Gioacchino Natoli (Milano, Italy)**
Fidelity in lineage determination and inducible gene expression in macrophages

16:50 | General Discussion

17:15 | Poster Walk

18:15 | NIBIT General Assembly

19:30 | Welcome reception

OCTOBER 23

SESSION 3 B AND T CELLS IN CANCER

Chairs: Marcella Tazzari, Claudio Tripodo

9:00 | **Isaias Hernandez (Paris, France)**
Shaping B cells via neuroimmune signals: toward better checkpoint inhibitor responses

09:20 | Selected abstract

09:30 | Selected abstract

09:40 | Selected abstract

09:50 | **Silvia Piconese (Roma, Italy)**
BRCAing bad: Tregs in the tumor microenvironment

10:10 | General discussion

10:30 | Coffee break

SESSION 4 AI IN IMMUNE ONCOLOGY FROM RESEARCH TO CLINIC

Chairs: Matteo Benelli, Arsala Prelaj

11:00 | **Daniel Truhn (Aachen, Germany)**
Healing with words - Large language models in oncology

11:20 | Selected abstract

11:30 | Selected abstract

11:40 | Selected abstract

11:50 | **Arsala Prelaj (Milano, Italy)**
AI for first Line immunotherapy prediction: from NSCLC to pancancer

12:10 | General discussion

13:00 | Lunch

FRIDAY

SESSION 5
EMPOWERING IMMUNE CELLS FOR ADOPTIVE CELL THERAPY
Chairs: Roberta Sommaggio

14:00	Concetta Quintarelli (Roma, Italy) <i>Innovative Applications of CAR-T Cells in Emerging Clinical Indications</i>
14:20	Selected abstract
14:30	Selected abstract
14:40	Ruggero De Maria (Roma, Italy) <i>Development of CAR T cell therapies for colorectal cancer</i>
15:00	Selected abstract
15:10	Chiara Bonini (Milano, Italy) <i>Genome editing to overcome T cell exhaustion</i>
15:30	General discussion
16:00	Coffee break
16:30	Poster Walk
17:30	PEZCOLLER KEYNOTE LECTURE <i>Chair: Mario Paolo Colombo</i> Marco Colonna (St. Louis, USA) <i>Harnessing Innate Immune Receptors in Cancer and Neurodegeneration</i>
18:20	Session ends
20:00	Social Dinner

OCTOBER 24

SESSION 6
IMMUNOTHERAPY. WHERE WE ARE AND WHERE WE ARE GOING
Chairs: Lorenzo D'Ambrosio

8:30 | **Tina Cascone (Houston, USA)**
Unraveling the complexities of tumor associated macrophages for anti-cancer therapy

8:50 | Selected abstract

9:00 | Selected abstract

9:10 | **Sara Lonardi (Padova, Italy)**
Immunotherapy role in GI tumors

9:30 | Selected abstract

9:40 | **Paolo Ascierto (Napoli, Italy)**
Neoadjuvant immunotherapy in the treatment of melanoma

10:00 | General discussion

10:30 | Coffee break

SATURDAY

**SESSION 7
NEW TARGETS IN IMMUNE-ONCOLOGY**

Chairs: Pier Francesco Ferrucci, Sheila Spada

10:45	Dario Neri (Zürich – Switzerland) <i>Ligand-based delivery of cytokines and other payloads: from the bench to the clinic</i>
11:05	Selected abstract
11:15	Selected abstract
11:25	Selected abstract
11:35	Flavio Curnis (Milano, Italy) <i>Blockade of $\alpha\beta6$ and $\alpha\beta8$ integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth</i>
11:55	General discussion
12:20	PARMIANI KEYNOTE LECTURE <i>Chair: Maria Rescigno</i> Laurence Zitvogel (Paris, France) <i>Bile acids are central in gut dysbiosis associated with cancer immune resistance</i>
13:00	NIBIT Awards Nominations
13:30	Adjourn

OCTOBER 25

VENUE

Accademia Navale
Livorno - IT

REGISTRATION FEES

Participant over 35 – NIBIT* & AIOM member	€ 250,00 VAT included
Participant under 35 – NIBIT* & AIOM member	€ 150,00 VAT included
Post Doc – NIBIT* & AIOM member	€ 150,00 VAT included
PhD Student – NIBIT* & AIOM member	€ 150,00 VAT included
Resident – NIBIT* & AIOM member	€ 150,00 VAT included
Non member (all categories)**	€ 350,00 VAT included
Undergraduate student	Free of charge

Social dinner
Open to all registered participants

Registration Fee

€ 50,00 VAT included

* NIBIT member with settled payment of membership fee for 2024 and 2025

** Membership fee for 2025 is € 50; to become a member please fill in the form on www.nibit.org

To register, please access the link [here](#)

CALL FOR ABSTRACT

All participants are encouraged to submit an abstract in English.

The abstracts will be reviewed by the Scientific Committee and selected for oral or poster presentation.

When submitting the abstract, presenting authors must select one of the following topics

- Myeloid cells in cancer
- Uncovering the molecular interactions within the tumor microenvironment
- B and T cells in cancer
- AI in immune oncology from research to clinic
- Empowering immune cells for adoptive cell therapy
- Immunotherapy. Where we are and where we are going
- New targets in immune-oncology

The abstract should respect the following guidelines:

- The abstract must be submitted in English.
- Abstract title should be max 250 characters (spaces included) and should reflect the content of the abstract.
- Commercial names may not be used in the abstract title.
- No more than 10 authors can be listed. Only institutional affiliations, cities and countries
- should follow. One of the authors must be flagged as “Presenting author”.

- Abstracts should be organized under the headings:
- Introduction
- Methods
- Results
- Conclusions
- Tables and figures can be uploaded as a separate file (JPG, max 1 page)
- The online abstract submission procedure will not accept abstracts that exceed 500 words
- Abbreviations may be used if standard or if spelled out and defined at the first use.
- Compounds should be mentioned with the generic name, in lower case. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”

Abstract Selection Process

The Scientific Committee will make the selection of abstracts for the oral or poster presentation.

Please note that submitting an abstract does not constitute registration for the meeting.

To submit your abstract please access the link [here](#)

TRAVEL GRANTS

NIBIT will offer a limited number of Travel Grants.

The Grant will cover the travel expenses up to the amount of € 500. The reimbursement will be provided by bank transfer after the end of the meeting, upon receipt of flight and/or ground transportation tickets/invoices.

To be eligible you have to:

- Be the presenting author of a submitted abstract
- Be born after 1 November 1985

To apply, please upload a CV or a bio sketch, including your publications, when submitting the abstract. Applications are subject to approval by the Scientific Committee

C.M.E. ACCREDITATION

Provider: Achelois Srl – ID 7362

The Congress was granted 15 C.M.E. credits from the Italian Ministry of Health for the following specialties:

- Physicians specialized in allergology and clinical immunology, pathological anatomy, clinical biochemistry, dermatology and venerology, hematology, oncology.
- Biologists.
- Biomedical laboratory technician.

Obiettivo formativo: Contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultra specialistica, ivi incluse le malattie rare e la medicina di genere (18)

UNDER THE AUSPICES



ACKNOWLEDGMENTS

